Prokopenko I; Langenberg C; Florez JC; et al. (2009). „Variants in MTNR1B influence fasting glucose levels”. Nat. Genet. 41 (1): 77—81. PMC2682768. PMID19060907. doi:10.1038/ng.290.CS1 одржавање: Експлицитна употреба et al. (веза); Lyssenko V; Nagorny CL; Erdos MR; et al. (2009). „Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion”. Nat. Genet. 41 (1): 82—8. PMID19060908. doi:10.1038/ng.288.CS1 одржавање: Експлицитна употреба et al. (веза); Bouatia-Naji N; Bonnefond A; Cavalcanti-Proença C; et al. (2009). „A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk”. Nat. Genet. 41 (1): 89—94. PMID19060909. doi:10.1038/ng.277.CS1 одржавање: Експлицитна употреба et al. (веза)
Rivara S; Lodola A; Mor M; et al. (2007). „N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands”. J. Med. Chem. 50 (26): 6618—26. PMID18052314. doi:10.1021/jm700957j.CS1 одржавање: Експлицитна употреба et al. (веза)
Bedini A; Spadoni G; Gatti G; et al. (2006). „Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands”. J. Med. Chem. 49 (25): 7393—403. PMID17149869. doi:10.1021/jm060850a.CS1 одржавање: Експлицитна употреба et al. (веза)
Prokopenko I; Langenberg C; Florez JC; et al. (2009). „Variants in MTNR1B influence fasting glucose levels”. Nat. Genet. 41 (1): 77—81. PMC2682768. PMID19060907. doi:10.1038/ng.290.CS1 одржавање: Експлицитна употреба et al. (веза); Lyssenko V; Nagorny CL; Erdos MR; et al. (2009). „Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion”. Nat. Genet. 41 (1): 82—8. PMID19060908. doi:10.1038/ng.288.CS1 одржавање: Експлицитна употреба et al. (веза); Bouatia-Naji N; Bonnefond A; Cavalcanti-Proença C; et al. (2009). „A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk”. Nat. Genet. 41 (1): 89—94. PMID19060909. doi:10.1038/ng.277.CS1 одржавање: Експлицитна употреба et al. (веза)
Rivara S; Lodola A; Mor M; et al. (2007). „N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands”. J. Med. Chem. 50 (26): 6618—26. PMID18052314. doi:10.1021/jm700957j.CS1 одржавање: Експлицитна употреба et al. (веза)
Bedini A; Spadoni G; Gatti G; et al. (2006). „Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands”. J. Med. Chem. 49 (25): 7393—403. PMID17149869. doi:10.1021/jm060850a.CS1 одржавање: Експлицитна употреба et al. (веза)